Editorial Journal of controlled release : official journal of the Controlled Release Society. 2018 Dec 28:292:277-278. doi: 10.1016/j.jconrel.2018.11.021 Q111.52025
Different phase behaviors of enzalutamide amorphous solid dispersions
エンザルутamide无定形固体分散体的不同相行为 翻译改进
作者单位 +展开
作者单位
DOI: 10.1016/j.jconrel.2018.11.021 PMID: 30527060
摘要 中英对照阅读
Keywords：enzalutamide; amorphous solid dispersions
相关内容
-
A comparative study on in vitro and in vivo characteristics of enzalutamide nanocrystals versus amorphous solid dispersions and a better prediction for bioavailability based on "spring-parachute" model
恩扎卢胺纳米晶体与无定形固体分散体的体外和体内特征比较研究及基于“弹簧-降落伞”模型更好的预测生物利用度
International journal of pharmaceutics. 2022 Nov 25:628:122333.
-
Moisture-induced phase separation and recrystallization in amorphous solid dispersions
固态分散体中水分诱导的相分离及重结晶现象
International journal of pharmaceutics. 2017 Oct 30;532(1):635-646.
-
Crystallinity: A Complex Critical Quality Attribute of Amorphous Solid Dispersions
无定形固体分散体的复杂关键质量属性结晶度研究
Molecular pharmaceutics. 2023 Oct 2;20(10):4802-4825.
-
Determination of precipitation inhibitory potential of polymers from amorphous solid dispersions
来自无定形固体分散体的聚合物的降水抑制潜力的测定
Drug development and industrial pharmacy. 2018 Dec;44(12):1933-1941.
-
Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations
利托那韦-peg 8000无定形固体分散体的体内外评价研究
Journal of pharmaceutical sciences. 2004 Mar;93(3):563-70.
-
Antisolvent Recrystallization Strategy to Screen Appropriate Carriers to Stabilize Filgotinib Amorphous Solid Dispersions
用于稳定Filgotinib无定形固体分散体的抗溶剂重结晶策略筛选合适的载体物质
Journal of pharmaceutical sciences. 2018 Jun;107(6):1624-1632.
-
New Strategies for Improving the Development and Performance of Amorphous Solid Dispersions
改善无定形固体分散体开发和性能的新策略
AAPS PharmSciTech. 2018 Apr;19(3):978-990.
-
Homogeneity of amorphous solid dispersions - an example with KinetiSol®
无定形固体分散体的均一性-以KinetiSol®为例
Drug development and industrial pharmacy. 2019 May;45(5):724-735.
